Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MOGAT2 | Q3SYC2 | 5/20 | 0.41 |
| ▸ | KDR | P35968 | 10/20 | 0.40 |
| ▸ | BRAF | P15056 | 6/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5426991 | 0.87 | KDR (0.42) | MOGAT2KDRBRAFMAPK14CYP3A4 | |
| SCHEMBL545003 | 0.83 | ABL1 (0.47) | MOGAT2KDRBRAFMAPK14 | |
| SCHEMBL545000 | 0.81 | BRAF (0.44) | MOGAT2KDRBRAFCYP3A4 | |
| SCHEMBL545457 | 0.78 | KDR (0.49) | KDRBRAFMAPK14 | |
| SCHEMBL546196 | 0.75 | BRAF (0.54) | KDRBRAF | |
| SCHEMBL5416318 | 0.73 | NFKB1 (0.46) | KDRBRAFMAPK14NPC1RAB9A | |
| SCHEMBL5417651 | 0.73 | BRAF (0.54) | KDRBRAFCYP3A4NPC1RAB9A | |
| SCHEMBL10199947 | 0.72 | BRAF (0.47) | KDRBRAF | |
| SCHEMBL5419921 | 0.71 | NPC1 (0.48) | KDRBRAFMAPK14NPC1RAB9A | |
| SCHEMBL545055 | 0.70 | RAF1 (0.45) | KDRBRAFCYP3A4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | MOGAT2 2524/4885KDR 1264/4885BRAF 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.